Bonne Lawrence, Verslype Chris, Laenen Annouschka, Cornelissen Sandra, Deroose Christophe M, Prenen Hans, Vandecaveye Vincent, Van Cutsem Eric, Maleux Geert
Department of Radiology, University Hospitals Leuven, Belgium.
Department of Hepatology and Gastroenterology, University Hospitals Leuven, Belgium.
Radiol Oncol. 2017 Feb 22;51(1):74-80. doi: 10.1515/raon-2017-0007. eCollection 2017 Mar 1.
The aim of the study was to retrospectively evaluate the symptom control, tumour response, and complication rate in patients with liver-predominant metastatic neuroendocrine tumours treated with transarterial chemoembolization using doxorubicin-eluting superabsorbent polymer (SAP) microspheres.
Patients with neuroendocrine liver metastases who underwent hepatic transarterial chemoembolization using doxorubicin-eluting SAP-microspheres (50-100 μm Hepasphere/Quadrasphere Microsphere® particles, Merit Medical, South Jordan, Utah, USA) were included in this study. Pre-and post-procedure imaging studies were evaluated to assess short and intermediate-term tumour response using modified RECIST criteria. Symptom relief and procedure-related complications were evaluated.
A total of 27 embolization procedures were performed on 17 patients. Twelve of 17 patients (70%) were symptomatic, including carcinoid syndrome (n = 8) and severe, uncontrollable hypoglycemia (n = 4). Eight of 12 patients (67%) had complete symptom relief, and the remaining 4 (33%) had partial relief. One patient developed ischemic cholecystitis (6%). No other hepatobiliary complications occurred. Short-term and intermediate-term imaging follow-up was available for 15/17 patients (88%) and 12/14 patients (86%) respectively. At short-term follow-up (< 3 months), 14 patients (93%) showed partial response and the remaining patient had progressive disease (7%). At intermediate-term imaging follow-up (> 3 months), partial response, stable disease and progressive disease were found respectively in 7 (58%), 3 (25%) and 2 (17%) patients.
Chemoembolization with doxorubicin-eluting SAP-microspheres is a safe and effective treatment option for neuroendocrine liver metastases and is associated with a low complication rate. In particular, no clinically evident liver necrosis or bile duct complications were encountered.
本研究旨在回顾性评估使用载阿霉素超吸收聚合物(SAP)微球经动脉化疗栓塞治疗以肝脏为主的转移性神经内分泌肿瘤患者的症状控制、肿瘤反应及并发症发生率。
本研究纳入了使用载阿霉素SAP微球(50 - 100μm Hepasphere/Quadrasphere Microsphere®颗粒,美国犹他州南乔丹市美力医疗公司)行经肝动脉化疗栓塞的神经内分泌肝转移患者。对术前和术后的影像学检查进行评估,采用改良的RECIST标准评估短期和中期肿瘤反应。评估症状缓解情况及与手术相关的并发症。
共对17例患者进行了27次栓塞手术。17例患者中有12例(70%)有症状,包括类癌综合征(8例)和严重的、无法控制的低血糖(4例)。12例有症状的患者中,8例(67%)症状完全缓解,其余4例(33%)部分缓解。1例患者发生缺血性胆囊炎(6%)。未发生其他肝胆并发症。分别有15/17例患者(88%)和12/14例患者(86%)进行了短期和中期影像学随访。在短期随访(< 3个月)时,14例患者(93%)显示部分缓解,其余1例患者疾病进展(7%)。在中期影像学随访(> 3个月)时,分别有7例(58%)、3例(25%)和2例(17%)患者出现部分缓解、疾病稳定和疾病进展。
使用载阿霉素SAP微球进行化疗栓塞是治疗神经内分泌肝转移的一种安全有效的治疗选择,且并发症发生率低。特别是未出现临床上明显的肝坏死或胆管并发症。